Sonrotoclax Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 26, 2026

The clinical evidence base for Sonrotoclax comprises 2 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Leukemia, Myeloid, Acute. Most recent publication: Risk-stratified treatment of sonrotoclax with chemotherapy in newly diagnosed acute myeloid leukemia: a study protocol., Future Oncol, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Risk-stratified treatment of sonrotoclax with chemotherapy in newly diagnosed acute myeloid leukemia: a study protocol.
Zhang Y, Wu M, Jin Z, et al. · Future Oncol · 2025
PubMed: PMID 40008672 · NCT06497062 · Leukemia, Myeloid, Acute
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Al-Sawaf O, Ligtvoet R, Robrecht S, et al. · Nat Med · 2024
PubMed: PMID 38071379 · NCT04271956 (CLL-RT1)

Publications by year

2024–2025: 2 publications.

2024

2025

Publications by indication

Leukemia, Myeloid, Acute (1)

Risk-stratified treatment of sonrotoclax with chemotherapy in newly diagnosed acute myeloid leukemia: a study protocol.
Future Oncol · 2025 · PMID 40008672 · NCT06497062

Publications by journal

Future Oncol1 paper
Nat Med1 paper

All Sonrotoclax publications (2)

2025 (1 paper)

Risk-stratified treatment of sonrotoclax with chemotherapy in newly diagnosed acute myeloid leukemia: a study protocol.
Zhang Y, Wu M, Jin Z, et al. · Future Oncol · 2025 · Derived
PubMed: PMID 40008672 · NCT06497062 · Leukemia, Myeloid, Acute

2024 (1 paper)

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Al-Sawaf O, Ligtvoet R, Robrecht S, et al. · Nat Med · 2024 · Derived
PubMed: PMID 38071379 · NCT04271956 (CLL-RT1)

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 26 May 2026 17:54:08 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).